Clinical Trial Update: Open-Label, Dose-Escalating Study Assessing Safety, Tolerability, Efficacy, of RP103 in Mitochondrial Disease [Phase 2]

View source ↗

Summary

Phase 2 open-label, dose-escalation study of RP103 to assess safety, tolerability, and efficacy in inherited mitochondrial diseases, including Leigh syndrome; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Leigh Syndrome
• Mitochondrial Disease

Drugs mentioned

• RP103

Snippet

Sponsor: Amgen | Conditions: Inherited Mitochondrial Disease, Including Leigh Syndrome | Phase 2 | Status: COMPLETED | Results posted: 2017-11-13